It has been suggested that vaccination prior to infection may direct the mutational evolution of human immunodeficiency virus type 1 (HIV-1) to a less fit virus, resulting in an attenuated course of disease. The present study was initiated to explore whether prior immunization might prevent the reversion of the virus to the wild-type form. Mamu-A*01 monkeys were vaccinated to generate a cytotoxic T-lymphocyte response to the immunodominant Gag p11C epitope and were then challenged with a cloned pathogenic CXCR4-tropic simian-human immunodeficiency virus (SHIV) expressing a mutant Gag p11C sequence (⌬p11C SHIV). The epitopic and extraepitopic compensatory mutations introduced into gag of ⌬p11C SHIV resulted in attenuated replicative capacity and eventual reversions to the wild-type Gag p11C sequence in naïve rhesus monkeys. However, in vaccinated rhesus monkeys, no reversions of the challenge virus were observed, an effect that may have been a consequence of significantly decreased viral replication rather than a redirection of the mutational evolution of the virus. These findings highlight the multifactorial pressures that affect the evolution of primate immunodeficiency viruses.
CD8
ϩ cytotoxic T-lymphocyte (CTL) responses are important for controlling replication of human immunodeficiency virus type 1 (HIV-1) in humans and simian immunodeficiency virus (SIV) in rhesus monkeys (6, 15, 19, 25, 32, 37, (39) (40) (41) . However, the accumulation of mutations in dominant epitopes of these viruses can undermine this immune control (1, 8, 13, 18, 28) . It has been proposed that a preexisting memory-specific CTL response elicited by vaccination prior to HIV-1/SIV infection might change the epitope specificity or the mutational pattern of the infecting virus (9) . It is also possible that vaccine-induced cellular immunity might diminish the level of virus replication in individuals following infection and in doing so decrease the rate of accumulation of viral mutations and the likelihood of emergence of viruses that can escape CTL recognition. Our laboratory has previously described a rare SHIV-89.6P escape virus that contains a mutation in the dominant Mamu-A*01-restricted Gag p11C C-M (CTPYDINQM) epitope (3, 4) . The emergence of this viral variant was associated with an increase in viral load and the eventual death of the previously vaccinated rhesus monkey 798. Analysis of the escape virus demonstrated a threonine-to-isoleucine mutation at amino acid position 47 (T47I) of the SIV capsid protein, which corresponds to position 2 of the Gag p11C epitope. This T47I mutation abrogated binding to the Mamu-A*01 class I molecule, allowing the virus to escape from recognition by the dominant epitope-specific CTL population (4) . In addition to the T47I mutation, a downstream isoleucine-to-valine (I71V) substitution was found to be required for the viability of the escape virus in vitro (12, 29, 30, 42) .
The present studies were initiated to study the effects of prior vaccination on Gag p11C sequence reversion by infecting monkeys with a simian-human immunodeficiency virus (SHIV) clone containing the gag mutations found in the escape virus that evolved in monkey 798. We first explored the effects of these mutations in vivo by infecting naïve Mamu-A*01 ϩ rhesus monkeys with a cloned SHIV (⌬p11C SHIV) containing both the Gag p11C T47I mutation and the downstream I71V compensatory substitutions. We then determined whether vaccination prior to infection could generate a cellular immune response that might alter the expected pattern of virus mutation in the immunodominant Mamu-A*01-restricted Gag p11C epitope of ⌬p11C SHIV.
MATERIALS AND METHODS
Animals, vaccination, and viral challenge. The rhesus monkeys used in this study were maintained in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) for Harvard Medical School and the Guide for the Care and Use of Laboratory Animals (25a). Rhesus monkeys were screened for the presence of the Mamu-A*01 allele using a PCR-based technique as previously described (17) . Naïve animals were challenged intravenously (i.v.) with 1 ϫ 10 8 RNA copies of wild-type (WT) SHIV-89.6P (n ϭ 4). Immunized Mamu-A*01 ϩ rhesus monkeys (n ϭ 3) were first vaccinated intramuscularly (i.m.) with plasmid DNA and then boosted 18 weeks later with 10 12 viral particles of recombinant adenovirus type 5 (rAd5) expressing SIV Gag-Pol-Nef and HIV-1 Env proteins. These monkeys were then challenged i.v. 14 weeks following rAd5 boost immunization with 1 ϫ 10 8 RNA copies of the Gag p11C mutant (⌬p11C) SHIV, a virus constructed from the SHIV-KB9 clone to contain a Gag p11C epitope mutation and a downstream compensatory substitution in gag, which allow the generation of replication-competent virus (3, 29, 42) .
Virus. The wild-type SHIV-89.6P used to infect immunized rhesus monkeys was derived from in vivo passage of SHIV-89.6, a chimeric virus consisting of the SIVmac239 backbone and a primary patient CCR5/CXCR4 dual-tropic HIV-1 89.6 envelope gene (33) (34) (35) . To produce mutant ⌬p11C SHIV for infection of immunized rhesus monkeys, the proviral plasmids for ⌬p11C SHIV were transfected into CEMx174 cells (American Type Culture Collection [ATCC]) by the DEAE-dextran method (16) . To monitor for virus production, culture supernatants were assessed for SIV p27 antigen using an SIV core antigen enzyme-linked immunosorbent assay (ELISA; Beckman-Coulter). Supernatant was harvested every week for 3 weeks, pooled, and aliquoted into 1-ml quantities for use in subsequent infection studies. Before they were pooled, viruses were sequenced to confirm the presence of the gag mutations using a OneStep reverse transcription-PCR (RT-PCR) kit (Qiagen) with the primers gag-forward (5Ј-AGCACCATC TAGTGGCAGAGGA-3Ј) and gag-reverse (5Ј-GAAATGGCTCTTTTGGCCC TT-3Ј). RT-PCR products were purified using a QIAquick PCR purification kit (Qiagen), cloned into the pGEM-T Easy vector (Promega), and transformed into competent Escherichia coli DH5␣ (Invitrogen). Plasmids were purified from individual transformed colonies using a Qiagen miniprep kit and were then subjected to T7/SP6 dideoxy sequencing using an ABI 3730 DNA analyzer.
gag point mutations. To produce ⌬p11C SHIV proviral plasmids, the gag position 2 p11C mutation (T47I) and downstream compensatory mutation (I71V) (29, 30, 42) were introduced into the SHIV-KB9 5Ј plasmid provided by Joseph Sodroski from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program. Mutations were created by PCR mutagenesis with a QuikChange kit (Stratagene). Oligonucleotide primers T47I-Forward (5Ј-CAGGCACTGTCAGAA GGTTGCATCCCCTATGACATTAATCAGATGTTAAATTG-3Ј) and T47I-Reverse (5Ј-CAATTTAACATCTGATTAATGTCATAGGGGATGCAACCTTCT GACAGTGCCTG-3Ј) were used to change Thr (ACC) to Ile (ATC). Primers I71V-Forward (5Ј-GCGGCTATGCAGATTATCAGAGATGTTATAAACGAG GAGGCTGCAGATTG-3Ј) and I71V-Reverse (5Ј-CAATCTGCAGCCTCCTCG TTTATAACATCTCTGATAATCTGCATAG CCGC-3Ј) were used to change Ile (ATT) to Val (GTT).
Viral load. The numbers of viral RNA copies per ml virus stock or plasma were quantified using an ultrasensitive branched DNA detection assay with a detection limit of Ͼ125 RNA copies per ml (Siemens).
gag sequencing. Viral RNA was isolated from plasma of SHIV-infected rhesus monkeys by using a QIAamp virus RNA isolation kit (Qiagen). Virus sequence analyses were performed using primers gag-forward (5Ј-AGCACCATCTAGTG GCAGAGGA-3Ј) and gag-reverse (5Ј-GAAATGGCTCTTTTGGCCCTT-3Ј). RT-PCR products were purified using a QIAquick PCR purification kit (Qiagen), cloned into the pGEM-T Easy vector (Promega), and transformed into competent E. coli DH5␣ (Invitrogen). Plasmids were purified from individual transformed colonies using a Qiagen miniprep kit and then subjected to T7/SP6 dideoxy sequencing using an ABI 3730 DNA analyzer.
Antibodies, tetramers, and peptides. The monoclonal antibodies (MAbs) used in this study were directly coupled to fluorescein isothiocyanate (FITC) or allophycocyanin (APC). The following MAbs were used: FITC-conjugated anti-CD8␣ (clone 7PT3F9; Beckman Coulter) and APC-conjugated anti-CD3 (clone FN18; BioSource International). Mamu-A*01/p11C/␤2m (SIV Gag) tetramer complexes were prepared as previously described (2, 7, 20, 26) . Briefly, phycoerythrin (PE)-labeled ExtrAvidin (Sigma-Aldrich) was mixed stepwise with biotinylated Mamu-A*01/peptide complexes at a molar ratio of 1:4 to produce the tetrameric complexes. Gag p11C (CTPYDINQM) peptides were obtained from QCB/Biosource (Hopkinton, MA). Lyophilized peptides were dissolved in a minimum volume of dimethyl sulfoxide (DMSO; Sigma-Aldrich), diluted to a stock peptide concentration of 15 mg/ml in water containing 5 mM dithiothreitol (DTT; Sigma-Aldrich), and then frozen at Ϫ70°C in aliquots. Before use, peptides were diluted to a working concentration in RPMI 1640 medium (Mediatech) supplemented with glutamine, 12% fetal calf serum (FCS), penicillin, streptomycin, and gentamicin.
Tetramer staining and flow cytometry. Whole-blood specimens were stained with Mamu-A*01/p11C/␤2m for 30 min at room temperature. Cells were then stained with a mixture of APC-anti-CD3 and FITC-anti-CD8␣ MAbs for 30 min. Whole-blood specimens (100 l) were lysed using a Q-prep workstation (Beckman-Coulter) before being fixed in 1.5% formaldehyde. A total of 3 ϫ 10
ϩ T cells were acquired using a FACSCalibur flow cytometer, and data were analyzed using CellQuest software (BD Biosciences).
Statistical analysis. All statistical differences between groups were calculated by the Mann-Whitney test using the GraphPad Prism program (version 4.03). A P value of Ͻ0.05 between groups was considered statistically significant.
RESULTS
⌬p11C SHIV exhibits delayed replication kinetics in vitro and diminished pathogenicity in vivo. To generate ⌬p11C SHIV, the T47I and I71V mutations were introduced into the SHIV-KB9 construct (a molecular clone of SHIV-89.6P) through site-directed mutagenesis (Fig. 1A) . We examined the replication kinetics of the newly generated ⌬p11C SHIV in peripheral blood mononuclear cells (PBMCs) isolated from the blood of naïve Mamu-A*01 ϩ rhesus monkeys by monitor- ϩ T-lymphocyte counts on day 0 and later time points are compared using the Mann-Whitney test ( * , P Ͻ 0.03; n.s., not significant).
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ing SIV Gag p27 antigen production in culture supernatants using an ELISA. An equivalent of 40 ng p27 of either WT or ⌬p11C SHIV was used to infect 2 ϫ 10 6 PBMCs. Previously reported data for cloned SIVmac239 containing the T47I/I71V mutations had shown early in vitro replication kinetics in rhesus monkey PBMCs that were indistinguishable from those of the wild-type cloned virus (42) . In contrast to these findings, ⌬p11C SHIV exhibited a delay in reaching peak replication in vitro compared to WT SHIV, but there was no significant difference in the magnitude of peak replication (Fig. 1B) . Viral RNA was analyzed by sequencing from supernatants on days 3, 12, 20, and 28 after initiation of infection to confirm the absence or the presence of Gag p11C mutations in WT and ⌬p11C SHIV (data not shown). Demonstration of the delay in ⌬p11C SHIV peak replication in vitro suggests that the mutations associated with Gag p11C escape results in decreased SHIV fitness.
To evaluate the in vivo replication kinetics and pathogenicity of ⌬p11C SHIV, we infected naïve Mamu-A*01 ϩ rhesus monkeys (n ϭ 4/group) intravenously with 1 ϫ 10 8 RNA copies of either WT or ⌬p11C SHIV and monitored the viral load in the plasma of the rhesus monkeys using an SIVmac239 gag branched DNA detection assay. Interestingly, in contrast to the in vitro replication kinetics, the time to peak viremia and the magnitude of peak viremia were indistinguishable early in infection in the WT-and ⌬p11C SHIV-infected rhesus monkeys (Fig. 1C ). These differences in early replication kinetics in vitro and in vivo are likely due to differences in sampling frequencies, inoculum doses, and inherent in vivo and in vitro conditions. The fitness cost associated with the Gag p11C and asso- ciated mutations became apparent after week 7, as the ⌬p11C SHIV-infected rhesus monkeys had plasma viral loads 2 to 3.5 logs lower than those of WT SHIV-infected animals. To assess the pathogenicity of ⌬p11C SHIV, we examined the loss of total CD4 ϩ T-lymphocyte populations following infection in these animals. Both WT-and ⌬p11C SHIV-infected rhesus monkeys demonstrated lower CD4 ϩ T-lymphocyte counts within the first month following infection (Fig. 1D) . However, ⌬p11C SHIV infection did not cause as profound a depletion of CD4 ϩ T lymphocytes as the WT SHIV infection, since rhesus monkeys infected with ⌬p11C SHIV had higher circulating CD4 ϩ T-lymphocyte numbers at week 5 following infection. These data suggest that ⌬p11C SHIV was less pathogenic in vivo than WT SHIV.
Absence of Gag p11C-specific CD8 ؉ T-lymphocyte responses at peak viremia in naïve Mamu-A*01
؉ rhesus monkeys infected with ⌬p11C SHIV. While our laboratory has demonstrated that the downstream I71V mutation is required to compensate for the T47I Gag p11C mutation (29, 30, 42) , the stability of these substitutions in vivo during ⌬p11C SHIV infection of naïve Mamu-A*01 ϩ rhesus monkeys was unknown. Rapid reversion of the mutant Gag p11C epitope sequence to wild type has been observed in Mamu-A*01 ϩ rhesus monkeys within weeks of infection with SIVsmE660 variants containing only the position 2 Gag p11C mutation (5) . However, it is unclear how the downstream I71V compensatory mutation in ⌬p11C SHIV would affect the reversion rate of the T47I Gag p11C mutation. We assessed the in vivo stability of the T47I Gag p11C mutation in the presence of the compensatory I71V mutation by monitoring the induction of Gag p11C-specific CD8 ϩ T-lymphocyte responses through Gag p11C tetramer staining and gamma interferon (IFN-␥) enzyme-linked immunospot (ELISPOT) assays in both WT-and ⌬p11C SHIVinfected naïve Mamu-A*01 ϩ rhesus monkeys. We reasoned that the Gag p11C tetramer responses should be detected only in ⌬p11C SHIV-infected Mamu-A*01 ϩ rhesus monkeys if a reversion occurred in the Gag p11C epitope of the virus. Peak Gag p11C tetramer responses were observed following WT SHIV infection of Mamu-A*01 ϩ rhesus monkeys, comprising 5 to 25% of the total circulating CD8 ϩ T-lymphocyte population ( Fig. 2A) . Gag p11C-specifc IFN-␥ ELISPOT assay responses generated following WT SHIV infection were detectable by week 2 and ranged from 400 to 2,500 spot-forming cells (SFCs) per 1 ϫ 10 6 PBMCs (Fig. 2B) . In contrast, in ⌬p11C SHIVinfected Mamu-A*01 ϩ rhesus monkeys, there were no measurable Gag p11C-specific CD8 ϩ T-lymphocyte responses detected by tetramer staining or ELISPOT assay during peak viremia ( Fig. 2C and D) , suggesting that the epitope-mutant virus with the downstream compensatory mutation was unable to stimulate Gag p11C-specific CD8 ϩ T-lymphocyte responses. Consistent with this finding, all viral clones isolated from these rhesus monkeys before week 3 contained the T47I and I71V mutations that were present in the infecting virus inoculum (data not shown).
These data indicated that ⌬p11C SHIV replication could be controlled in the absence of dominant Gag p11C-specific CD8 ϩ T-lymphocyte responses. We reasoned that this control may be a result of compensating cellular immune responses with specificities for undefined viral epitopes. To explore this possibility, we assessed the extent of the global T-lymphocyte responses to SHIV proteins in WT and ⌬p11C SHIV-infected naïve rhesus monkeys through ELISPOT assays using pooled peptides spanning SIV Gag, SIV Pol, and HIV-1 Env. In WT SHIV infection, the predominant response postchallenge was directed toward SIV Gag, which was most likely comprised of responses focused on the single dominant Gag p11C epitope ( Fig. 2E and F) . Moderate Env-specific responses also developed, which may in part be comprised of Env p41A-specific responses. In contrast, in rhesus monkeys infected with ⌬p11C SHIV, there was a high T-lymphocyte IFN-␥ response to Gag (Fig. 2E) , with no contribution of Gag p11C-specific responses (Fig. 2F) . Furthermore, there were significantly higher Polspecific responses in all rhesus monkeys infected with ⌬p11C SHIV than in rhesus monkeys infected with WT SHIV. There was little contribution of Env p41A-and Pol p68A-specific responses to the overall higher Env-and Pol-specific T-lymphocyte responses seen in ⌬p11C SHIV-infected rhesus monkeys. These data suggest that compensating immune responses can control ⌬p11C SHIV replication in the absence of the dominant Gag p11C-specific cellular immune response. Sequence reversions in unvaccinated ⌬p11C SHIV-infected rhesus monkeys. Surprisingly, by week 5 we were able to detect very-low-frequency Gag p11C tetramer binding CD8 ϩ T-lymphocytes in the ⌬p11C SHIV-infected monkeys, ranging from approximately 0.01% to a maximum of 0.085% of peripheral blood CD8 ϩ T lymphocytes (Fig. 2C ). In addition, very-low-frequency Gag p11C-specific ELISPOT assay responses were detected in PBMCs of these monkeys as early as week 4 following infection, with maximal responses reaching 75 SFCs per 10 6 PBMCs (Fig.  2D) . Reversion to the wild-type virus sequence at positions 47 and 71 of Gag in some clones was confirmed by sequencing of plasma virus from ⌬p11C SHIV-infected monkeys sampled at weeks 9 and 19 postchallenge (Fig. 3A to D) . These data therefore suggest that Gag p11C-reverted viruses can emerge, even in the presence of the downstream I71V mutation, but are contained to low frequencies by Gag p11C-specific CD8 ϩ T-lymphocyte responses or through compensatory immune responses directed against other epitope specificities.
Vaccination induces immunity that enhances control of ⌬p11C SHIV and preserves CD4
؉ T-lymphocyte counts following infection. We then examined the effects of vaccination on Gag p11C reversion employing ⌬p11C SHIV as the challenge virus. We vaccinated three Mamu-A*01 ϩ rhesus monkeys with DNA and recombinant adenovirus expressing the SHIV genes SIV Gag, SIV Pol, and HIV-1 Env and then challenged them intravenously with 1 ϫ 10 8 viral copies of ⌬p11C SHIV. The viral loads in these vaccinated monkeys were compared to the viral loads in naïve monkeys previously infected with ⌬p11C SHIV, as shown in Fig. 1C . Interestingly, the time to peak viremia and the magnitude of ⌬p11C SHIV peak viremia in the vaccinated rhesus monkeys did not differ significantly from those in the naïve rhesus monkeys (Fig. 4A) . However, at 5 weeks postchallenge, the ⌬p11C SHIV loads in the vaccinated rhesus monkeys were significantly lower (P Ͻ 0.05) than the ⌬p11C SHIV loads in the naïve rhesus monkeys. In addition to enhanced viral control, vaccination conferred protection against initial CD4 ϩ T-lymphocyte depletion, which occurred between weeks 0 and 5 in naïve rhesus monkeys infected with ⌬p11C SHIV (Fig. 4B) . As expected, there were no significant cellular immune recall responses to Gag p11C following infection of vaccinated rhesus monkeys with ⌬p11C SHIV, as measured by tetramer staining and IFN-␥ ELISPOT assay (Fig. 5A and B, respectively) , confirming that vaccination can enhance control of ⌬p11C SHIV replication in the absence of the dominant Mamu-A*01-restricted Gag p11C response.
Significant increases in HIV-1 Env and SIV Pol pooledpeptide IFN-␥ ELISPOT assay responses in vaccinated rhesus monkeys following ⌬p11C SHIV infection. We also monitored IFN-␥ ELISPOT assay responses to SIV Gag, SIV Pol, and HIV-1 Env pooled peptides in these challenged monkeys. Even though robust secondary Gag-specific responses are typically seen in vaccinated rhesus monkeys following wildtype SHIV infection (36, 38) , no significant increases in Gag-specific responses were observed in vaccinated rhesus monkeys following challenge with ⌬p11C SHIV (Fig. 5C) . However, significant increases in HIV-1 Env-and SIV Polspecific responses (P Ͻ 0.05) were observed following ⌬p11C SHIV infection, with a notable contribution being provided by the well-described Mamu-A*01-restricted Env p41A epitope-specific response but not the Pol p68A epitope-specific response (7) (Fig. 5D) .
Gag p11C viral reversion frequency in challenged Mamu-A*01 ؉ rhesus monkeys. To determine whether vaccination prior to infection reduced the incidence of Gag p11C reversion in ⌬p11C SHIV-infected rhesus monkeys, we sequenced a 500-bp region of gag from multiple viral clones derived from plasma samples obtained from naïve and vaccinated rhesus monkeys infected with ⌬p11C SHIV. The sequences from plasma viral RNA at weeks 9 and 19 postchallenge are shown in Fig. 3 , and reversion frequencies are shown in Table 1 . Gag p11C sequence reversions with the downstream I71V compensatory mutation were detectable by week 9 in the naïve rhesus monkeys. In addition, by week 19, unvaccinated monkeys 89-98 and 156-06 also harbored viruses with the reverted downstream compensatory mutation. Gag p11C-specific CD8 ϩ Tlymphocyte responses were detectable at weeks 9 and 19 by tetramer and IFN-␥ ELISPOT assays (data not shown), consistent with the sequence reversions found in the naïve ⌬p11C SHIV-infected rhesus monkeys.
In contrast, no Gag p11C sequence reversions were detected in virus isolated from vaccinated rhesus monkeys at weeks 9 and 19 following ⌬p11C SHIV infection. Thus, vaccination prevented reversions from occurring. Of importance, undetectable or low viral loads (Table 1) were observed in these vaccinated, infected rhesus monkeys at weeks 9 and 19. These data suggest that vaccination may have prevented Gag p11C reversion either through the priming of Gag p11C-specific CD8 ϩ T-lymphocyte responses or priming for a global SHIV-specific T-lymphocyte response that diminished viral replication, which in turn diminished the generation of mutant viruses. a All monkeys were infected with ⌬p11C SHIV. b cDNAs were generated from plasma viral RNA of individual monkeys at weeks 9 and 19 postchallenge and cloned into the pGEM-T Easy (Promega) vector for sequencing. The first two data points represent the number of wildtype p11C sequences/total number of viral sequences tested, and data in parentheses represent (number of wild-type p11C sequences/total number of viral sequences) ϫ 100.
c Number of viral RNA copies per ml plasma. (4, 18, 31) . Moreover, the transmission of viruses with such CTL escape mutations to naïve hosts that share the relevant restricting major histocompatibility complex (MHC) class I allele with the donor can lead to early virus escape from immune control and rapid disease progression (11, 14, 21, 22) . The SHIV construct generated for the present study was modeled upon the CTL escape virus that was presumed to cause the death of a monkey that was vaccinated and then challenged with SHIV-89.6P (4). This virus mutant was generated so that it would be particularly stable, since a compensating downstream mutation that facilitated normal virus core assembly was included in the construct (29, 30, 42) . Nevertheless, the inoculation of naïve monkeys with this construct resulted in a less pathogenic infection than inoculation with wildtype SHIV-89.6P or SHIV-KB9, as characterized by lower setup viremia and slower CD4 ϩ T-cell depletion. The loss of pathogenicity is likely a consequence of the low replicative capacity of this mutant virus that was manifested both in vitro and in vivo. These data suggest that viral escape mutations associated with the immunodominant Gag p11C epitope did not provide a selective advantage to the escape mutant virus when it was transmitted to a naïve MHC-matched host.
It has been hypothesized that vaccination can induce cellular immune responses that may be able to abort or redirect the evolution of HIV/SIV mutations that are generated following infection (9) . The present study allowed us to test this hypothesis in the setting of preventing reversion of a CXCR4-tropic ⌬p11C SHIV mutant to a wild-type p11C sequence in the gag of the replicating virus. The vaccinated monkeys were protected against developing a back mutation from the mutant to the wild-type Gag epitope sequence in the absence of significant Gag p11C-specific cellular immune responses following infection. The findings in this study suggest that the vaccineinduced cellular immune response was probably not redirecting the evolution of the mutational pathway of the virus. Rather, the vaccine-induced immune response decreased the replication of the challenge virus in the infected monkeys and therefore decreased the rate at which the mutant virus could revert to wild-type virus. However, given that CXCR4-tropic SHIVs have been shown to be more easily controlled by vaccine regimens than CCR5-tropic HIVs/SIVs, our findings of vaccine-induced cellular immune responses preventing lentivirus escape by decreasing viral replication may not necessarily be reflected in the biology of infections of more physiologically relevant CCR5-tropic HIVs/SIVs.
Since a limited number of dominant epitope-specific CD8 ϩ CTL specificities mediate most of the CTL activity against a replicating virus, the elimination of a dominant epitope-specific CD8 ϩ CTL population might be expected to decrease substantially the effectiveness of an antiviral CTL response. In the present study, such a dominant epitope-specific cellular immune response was eliminated, yet the virus was controlled quite effectively in naïve and vaccinated monkeys. This effective control of the replication of the SHIV construct might be accounted for by the decreased intrinsic pathogenicity of the ⌬p11C mutant virus. However, the present data also indicate that the loss of p11C-specific CTL activity was associated with a compensatory increase in the T-cell responses to other epitopes of the virus. Thus, the monkeys infected with the mutant SHIV developed more robust cellular immune responses to the Env and Pol of SHIV than monkeys infected with wild-type SHIV. Moreover, they also developed strong responses to other regions of the Gag protein that do not develop when the virus expresses the immunodominant Gag p11C epitope. This observation is consistent with previous findings demonstrating that immunodomination mutes the cellular responses to multiple regions of the virus when the p11C-specific CD8
ϩ T-cell response is present (23) . There is a general consensus among investigators that increasing the breadth of CTL recognition of HIV/SIV should provide particularly effective immune control of viral replication (24, 27) . Some have suggested that eliminating dominant epitope-specific CTLs should uncover CTLs that recognize multiple other epitopes of the virus, increasing the breadth of the cellular immune response (10) . In fact, we have shown this to be the case in the present study, as elimination of the p11C epitope from the infecting SHIV resulted in the induction of a very broad CTL response. However, we could not determine whether this broad CTL response mediated particularly effective control of SHIV in vivo since the infecting virus was intrinsically less replication competent than the wild-type virus. This observation underscores the complexity of making focused changes in the sequence of an AIDS virus and attempting to draw conclusions concerning the ramifications of those changes. Further mapping of the responses elicited by ⌬p11C SHIV may aid in development of more potent vaccines that can elicit a broader repertoire of T-cell epitopes.
